Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + penpulimab
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Surufatinib + penpulimab is a combination therapy consisting of surufatinib, a small molecule multi-kinase inhibitor, and penpulimab, a humanized IgG1 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Surufatinib inhibits vascular endothelial growth factor receptors (VEGFR 1/2/3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF-1R), thereby inhibiting angiogenesis and modulating the tumor microenvironment by reducing tumor-associated macrophages. Penpulimab is a PD-1 inhibitor that restores T-cell mediated anti-tumor immune responses. This combination is being investigated for its synergistic potential in treating advanced solid tumors, including osteosarcoma and soft tissue sarcoma, where the anti-angiogenic and immunomodulatory effects of surufatinib may enhance the efficacy of PD-1 blockade.
- Other names
- surufatinib + penpulimab
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on surufatinib + penpulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + penpulimab.